Clinical Trials
12 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02849496 2026-05-22
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05372640 2026-05-13
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06982222 2026-05-13
Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT03939897 2026-04-29
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07474090 2026-03-16
STEPS-BC
Wake Forest University Health Sciences
Phase NA Not yet recruiting
NCT06315296 2026-03-03
An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer
Thomas Jefferson University
Phase NA Terminated
NCT04692103 2026-01-22
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
University of Washington
Phase 2 Active not recruiting
NCT04521764 2026-01-08
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
Mayo Clinic
Phase 1 Recruiting
NCT01714128 2021-10-25
FES-PET for Patients Treated on NCI Protocol 8762
Washington University School of Medicine
Phase NA Withdrawn
NCT04328194 2020-03-31
Autotaxin (ATX) as a Marker for Breast Cancer
Assiut University
Phase NA Unknown
NCT00632541 2018-02-14
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
Hoosier Cancer Research Network
Phase 2 Terminated